The document outlines the agenda for the 4th annual conference on peptide therapeutics, featuring workshops and presentations focused on oral delivery, protein-protein interactions, peptide characterization, and innovations in biopharmaceutical manufacturing. Key workshops include topics like Quality by Design (QbD) in process development and strategies for extending peptide half-lives, with participation from industry leaders. Attendees will gain insights into the latest technologies and challenges in peptide-based therapeutics, along with opportunities for networking and sponsorship.

1. QbD in Process Development and Manufacturing
13.30 - 17.30
Workshop Leader:
Alessandro Butté, Lecturer, ETH Zurich
BOOK BY 31ST MARCH 2017 AND SAVE £400
BOOK BY 28TH APRIL 2017 AND SAVE £200
BOOK BY 31ST MAY 2017 AND SAVE £100
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Wednesday 5th July 2017, Holiday Inn Kensington Forum, London, UK
www.peptidesevent.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
@SMIPHARM
#smipeptides
Oral Delivery of Peptides and Proteins
08.30 - 12.30
Workshop Leaders:
Roger New, Co-founder & CSO, Proxima Concepts Ltd
and Driton Vllasaliu, Senior Lecturer, University of Lincoln
HIGHLIGHTS IN 2017:
• Gather more in-depth knowledge about using LC-MS
applications for peptide purification from the key sessions
in the Liquid Chromatography and Mass Spectrometry
Techniques stream
• Listen to informative presentations on Protein-Protein
Interactions, featuring discussion points on antibodies, small
molecule drug discovery and peptidomimetic inhibitors
• Learn more about peptide characterisation from our expert
speakers discussing stability, purification, synthesis, and other
peptide properties
• Hear about strategies for peptide half-life extension, the
new technologies used in therapeutic peptide development,
production and manufacturing, and what the future trends are
for peptides in the biopharmaceutical industry
SMi present its 4th Annual Conference on...
PeptidesAddressing the latest peptide therapeutics advances
to accelerate discovery, development and delivery
Holiday Inn Kensington Forum, London, UK
CONFERENCE:
6TH - 7TH
WORKSHOPS: 5TH
JULY
2017
CHAIRS:
• John Reilly, Senior Research Investigator, Novartis
• Lutz Jermutus, Senior Director & Product Development
Team Leader, MedImmune
KEY SPEAKERS INCLUDE:
• Alastair Lawson, Vice President, Structural Biology, UCB
• Cecile Brocard, Director, Downstream Development,
Boehringer Ingelheim
• Jonathan Davis, Principal Scientist, Bristol-Myers Squibb
• Dieter Kadereit, Lab Head, Peptides & Insulins, IDD, R&D, Sanofi
• Marie Skovgaard, Director Medicinal Chemistry,
Zealand Pharma
• Marion King, Analytical Development Manager, Ipsen
Sponsored by

2. Register online at www.peptidesevent.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking
opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join
the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Bachem provides comprehensive services to the pharma and biotech industries. It specializes in the development of innovative, efficient
manufacturing processes and the reliable production of peptide-based APIs. The group has a global reach with more experience and know-
how than any other company in the industry. Bachem. Pioneering Partner for Peptides. www.bachem.com
Tepnel Pharma Services is an independent Contract Research Organisation which supports the drug development pipeline at the Rx/Dx
interface. With over 30 years of experience in supporting pharmaceutical, biopharmaceutical and biotechnology companies through
the provision of outsourced cGMP compliant Chemistry, Manufacturing and Control (CMC) and human genetics testing, Tepnel Pharma
Services is positioned to provide CMC support for drug development, whilst also providing a companion diagnostic solution which addresses
the requirements of personalised and stratified medicines. www.tepnelpharmaservices.com
Sponsored by
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
John Reilly,
Senior Research Investigator,
Novartis
PROTEIN-PROTEIN INTERACTIONS
OPENING ADDRESS:
09.10 Antibody-enabled small molecule drug discovery
•Protein-protein interactions
•Conformational definition of target proteins
•Allosteric modulation of dynamics
•Fragment library design and screening
Alastair Lawson, Research Fellow, Vice President Structural
Biology, UCB
09.50 Understanding the Structure Activity Relationship of the Nrf2-
KEAP1 protein-protein interaction site using an Nrf2-neh2 peptide
library design approach
•Activation of innate antioxidant responses holds much
therapeutic potential in neurodegenerative diseases, such as
Huntington’s disease
•Keap1-Nrf2 pathway plays a central role in cell protection
against oxidative and electrophilic stress
•Structure activity relationship (SAR) studies were performed on
Nrf2 to identify peptide inhibitors of the Nrf2/Keap1 protein-
protein interaction
•Inspiring medicinal chemistry efforts towards peptidomimetics
and macrocyclic inhibitors development
Elisabetta Bianchi, Head of Peptide Chemistry, IRBM Science Park
10.30 Morning Coffee & Networking Break
PEPTIDOMIMETIC INHIBITORS AND PEPTIDE NANOTECHNOLOGY
11.00 Synthesis of novel peptidomimetic inhibitors of Caspase I
•Proteomics and transcriptomic studies have shown a strong
induction of IL-1␤ expression in acne inflammatory skin lesions
•IL-1␤ usually exists in its pro-form which is cleaved to its active
form by the aspartic cysteine protease Caspase-1 upon
inflammatory stimulus
•Blocking Caspase I, therefore, presents an attractive option for
the development of a new generation of anti-acne medicine
•This presentation will concentrate on the synthesis of novel
peptidomimetic inhibitors of Caspase I
Craig Harris, Head of Research Synthesis, Nestlé Skin Health
11.40 Combinatorial Peptide Nanotechnology for Drug Discovery
•Peptide nondomains
•Receptor agonists
• A priori drug discovery
•From test tube to whole organism
Roger New, Co-founder & CSO, Proxima Concepts Ltd
12.20 Networking Lunch
13.30 Fusion Strategy for the Recombinant Expression of Therapeutic
Peptides in Microbial
•Non-Platform Process
•Expression in E. coli, Inclusion Bodies and Protein Refolding
•Protease Fusion Technology
•Production of Therapeutic Peptides at Industrial Scale
Cecile Brocard, Director, Downstream Development,
Boehringer Ingelheim
14.10 From peptide lead candidate to pharmaceutical drug product
•Process development, scaling-up and validation
•Characterisation and process validation
•Specifications and registration
•Specific challenges associated with contract manufacturing
service providers
Vincent Bille, Managing Director, Marble Pharma Consult
14.50 Afternoon Tea & Networking Break
LIQUID CHROMATOGRAPHY AND
MASS SPECTROMETRY TECHNIQUES
15.20 High Throughput Purification and Characterisation of Peptides
Using LC/MS/ELSD Techniques
•Peptide QC
•Purity analysis using LC/MS/ELSD techniques
•Peptide purification
•High Throughput purification workflow
Bhagyashree Khunte, Senior Principal Scientist, Pfizer
16.00 LC-MS a key technique to understanding the fate of impurities in
Ferring’s synthetic therapeutic peptides
•LC-MS a great tool to understand fate of impurities
•Separation is crucial as well as identification of impurities
•Identification of impurities originating from starting material,
synthesis, purification and degradation of peptides
•Examples from Ferring’s synthetic peptide portfolio
Jörgen Kjellgren Sjögren, Senior Research Scientist,
Ferring Pharmaceuticals
16.40 Mass-spectrometry based immunopeptidomics for personalised
cancer immunotherapy
•Biochemical extraction of HLA binding peptides form tumour
tissues
•Advanced mass-spectrometry analyses for identification and
validation of HLA binding peptides
•Immunopeptidomics in combination with genomics for
identification of clinically relevant neo-antigens
•Prioritisation of tumour antigens for vaccination
Michal Bassani-Sternberg, Head of Immunopeptidomics Unit,
CHUV and The Ludwig Cancer Institute
17.20 Chairman’s Closing Remarks and Close of Day One
Peptides
Day One | Thursday 6th July 2017 www.peptidesevent.com

3. Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING OPPORTUNITIES
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Honey De Gracia, SMi Marketing on +44 (0) 207 827 6102 or email: hdegracia@smi-online.co.uk
Lead Media Partner: Supported by
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Lutz Jermutus,
Senior Director and Product Development Team Leader,
MedImmune
HALF-LIFE EXTENSION OF PEPTIDES
OPENING ADDRESS:
09.10 Recent Progress in the Development of Once-Weekly GLP-1
Receptor Agonists
•Strategies for half-life extension
•Established products in the GLP-1 field
•Emerging technologies, including own data
Dieter Kadereit, Lab Head, Peptides & Insulins, IDD, R&D, Sanofi
09.50 Extending Drug Half-Life to Achieve Monthly Dosing? The Potential
of Veltis® Engineered Albumins for Optimised Dosing
•Short circulatory half-life represents a major obstacle for many
peptide-based therapeutics
•This can be significantly improved by conjugation or fusion to
albumin, due to increased size and recycling via the neonatal
Fc receptor (FcRn)
•The increased FcRn affinity of the Veltis® engineered albumins
translates to more than doubling of the already long half-life of
native sequence albumin
•We will describe rationally engineered albumins and their
application to improve delivery of peptides
Joanna Hay, Science Manager, Albumedix
10.30 Morning Coffee & Networking Break
11.00 From challenging peptide to drug candidate
– the dasiglucagon story
•Learnings from native glucagon
• Optimisation of soluble and chemically stable glucagon analogs
•Clinical summary
Marie Skovgaard, Director Medicinal Chemistry, Zealand Pharma
IMPROVING FUTURE PEPTIDE DEVELOPMENT
11.40 Peptides in the biopharmaceutical industry today and tomorrow
•Small versus big molecules – benefits and differences in
development & manufacturing of peptides
•Industrial pipelines and disease areas addressed by biotherapies
•NBEs versus NCEs
•Future trends in manufacturing
Frank Thielmann, PMO & Operational Excellence Lead, Novartis
12.20 Networking Lunch
13.30 Conquering a peptide optimisation challenge using protein
engineering techniques and deliberate potency reduction
•Challenge: Optimising gp41-binding peptide to be a
component of a tri-functional therapeutic
•Generated libraries of variant peptides fused to a globular
protein, expressed and purified in E. coli
•Reduced the potency of the parental peptide via truncation,
to allow favourable mutations to be recognised
•Final peptide became part of a tri-specific biologic therapeutic
with picomolar potency and broad spectrum against HIV
Jonathan Davis, Principal Scientist, Bristol-Myers Squibb
14.10 Optimisation of peptide stability
•Physical and chemical stability
•Methods for determination of physical and chemical stability
•Optimisation of peptide stability
Martin Will, Section Head MedChem, Sanofi
14.50 ReadyFlow - a first in class coagulant for controlling surgical
bleeding
•Unmet needs in the control of surgical bleeding and key factors
to determine success
•HX-P12 peptide: a first in class peptide coagulant
•Design of a particulate hydrogel formulation
•Current ReadyFlow formulation; challenges and progress
Renata Zbozien, Vice President R&D, Haemostatix
15.30 Afternoon Tea & Networking Break
MASS SPECTROMETRY APPLICATIONS AND
CHROMATOGRAPHY STRATEGIES
16.00 The use of high resolution mass spectrometry applications for both
development and commercial peptides
•Mass Spectrometry of peptides that involve ligation
technologies
•Mass Spectrometry for confirming the removal of solid phase
coupling reagents
•Mass Spectrometry for impurity identification in life cycle
management activities
Marion King, Analytical Development Manager, Ipsen
16.40 Purification, Characterisation and Physicochemical Properties
of Peptides within Discovery Chemistry
•Chromatographic purification strategies for cyclic and linear
peptides including SFC, LC and Flash methodologies
•Stoichiometry of final salt forms using Ion Chromatography
•Extraction strategy to remove TFA from final products
•Physicochemical Trend Analysis on final products
John Reilly, Senior Research Investigator,
Novartis Institutes for BioMedical Research
17.20 Chairman’s Closing Remarks and Close of Day Two
Peptides
www.peptidesevent.com Day Two | Friday 7th July 2017

4. Oral Delivery of Peptides and Proteins
Overview of the workshop:
Topics covered will include:
• Overview of routes across the intestinal cell wall
• Encapsulation technologies for peptides and proteins
• Research and development of absorption enhancement
technologies
• Application to peptide hormones and vaccine antigens –
case studies
Why should you attend this workshop:
An increasing number of therapeutic agents are being
developed which are based on peptides, usually made by
recombinant means. A drawback to their widespread use
is their sensitivity to breakdown in the gut, and the barrier to
crossing the intestinal cell wall, imposed by the size of these
molecules. Oral delivery is consequently a problem. Anybody
interested in developing new peptide-based therapeutics
should attend this workshop to find out the latest technologies
being developed, which, after a thirty-year gestation period,
are now beginning to yield successful outcomes.
Programme
08.30 Registration & Coffee
09.00 Opening Remarks
09.10 Session 1 – Overview of routes across the
intestinal cell wall
Transport via lymphatics or portal vein
09.50 Session 2 – Encapsulation technologies for
peptides and proteins
Liposomes, polymeric nanoparticles, SLNPs,
oil emulsions
10.30 Morning Coffee
11.00 Session 3 – Basic research on absorption
enhancement technologies
Comparison of different absorption enhancers
11.40 Session 4 – Case Studies with peptide hormones
and vaccine antigens
Preclinical and clinical trial results from around
the world
12.20 Closing Remarks
12.30 Close of Workshop
About the workshop leader:
Roger New studied chemistry at Oxford and obtained
a PhD in immunology at St Mary’s Hospital, London,
before going to work in Liverpool for 14 years, first at
the Department of Biochemistry, then at the School
of Tropical Medicine and Hygiene. His research activities have
centred on the creation of new technologies to improve the
therapy of disease, during which time he has devised patented
approaches to oral peptide delivery, vaccine carrier systems,
and a technology for discovery of new therapeutics. He has
acted as expert advisor in numerous institutions at home and
overseas, has written a textbook on liposomes, and is honorary
lecturer in Pharmaceutics at Kings College London. Dr New’s
laboratory was the first to demonstrate the in vivo efficacy of
liposomal amphotericin in leishmaniasis, a product which has
now been commercialised for over ten years. He went into
industry twenty years ago, first in Biocompatibles Ltd, then
Cortecs, and is currently Co-founder and Executive Director
of the biotech R&D company Proxima Concepts Ltd, with
laboratories based in London. Development of the peptide
delivery technology invented by Dr New has resulted in a
product for oral administration of insulin, now in Phase II clinical
trials, and licensed to large pharma in an emerging market.
About the organisation:
Proxima Concepts was founded in 2000, and
has devised four new technologies which it is
exploiting in the biopharmaceutics area:
1. Axcess – a vehicle for oral delivery of peptides and proteins,
including oral insulin in Phase II
2. Vaxcine–anoil-baseddeliveryvehiclefororaladministration
of vaccine antigens, with particular application to intestinal
and respiratory diseases.
3. Mozaic – a discovery technology for identifying building
blocks which, in combination, can form therapeutically
active structures.
4. Lexicon – A cyclic peptide scaffold designed to maximise
interactions with peptide cell receptors.
Workshop Leaders:
Roger New, Co-founder & CSO, Proxima Concepts Ltd
and Driton Vllasaliu, Senior Lecturer, University of Lincoln
HALF-DAY PRE-CONFERENCE WORKSHOP
Wednesday 5th July 2017
08.30 – 12.30
Holiday Inn Kensington Forum, London, UK

5. QbD in Process Development
and Manufacturing
Overview of the workshop:
In this workshop, the role of quality by design (QbD) in the
development of a process will be discussed. An overview on
QbD will be given from different perspectives (practical to
regulatory), with practical references to the development of
downstream operation and other types of pharmaceutical
processes. This introduction will be followed by an introduction
to Design of Experiments, with particular emphasis on design
techniques and common pitfalls. The course will be integrated
with notions on multivariate analysis (MVA), trying to answer
common questions on what MVA is, and why one should use
MVA in process development. Finally, additional modeling
technologies to aid process development will be discussed,
including the use of deterministic models, hybrid models and
the extraction of process information using spectroscopic
techniques.
Why should you attend this workshop:
This workshop is tailored for R&D people and for anyone willing to
discussnewtechnologies,intheframeofQbDandPATinitiatives,
to speed up process development and make it more robust.
References to current industrial initiatives (such as digitalisation,
big-data, machine learning and industry 4.0) will be discussed.
Programme
13.30 Registration & Coffee
14.00 Opening Remarks and Introductions
14.10 Session 1 – Introduction to QbD
A short overview on QbD and what it practically means
in the everyday R&D life will be done.
14.50 Session 2 – Design of Experiments
What is DoE and why DoE is useful in process
development. Overview on DoE techniques, limitations
and advanced designs. Discussion on how a wrong use
of DoE could become counterproductive.
15.30 Afternoon Tea
16.00 Session 3 – Multivariate Analysis
Introduction to multivariate analysis and the concept
behind this. Overview of main MVA techniques, their
objectives (clustering, regression, anomaly detection,
etc.) and main differences with non-multivariate
techniques.
16.40 Session 4 – Other advanced modelling techniques
Introduction to other techniques, including deterministic
models and hybrid models (combination of deterministic
and machine learning). An overview of the statistical
analysis of spectra coming from spectroscopic
techniques will be also discussed and how spectroscopy
can be integrated in process development (process
understanding,trajectoryanalysis,controlandprediction).
17.20 Closing Remarks
17.30 Close of Workshop
About the workshop leader:
Alessandro Butté received his Ph.D. in Chemical
Engineering in 2000 from ETH Zurich. After a two-year
post-doc at the Georgia Institute of Technology, he join
thegroupofProf.MorbidelliatETHZurichandcompleted
his habilitation in 2008. During this period, his research activities
focused on polymer engineering, production of nano-materials
for protein purification (monoliths by reactive-gelation) and
chromatography purifications of peptides, proteins and Mabs. In
2008, he joined Lonza as leader for downstream activities in the
sectors small molecules and peptides and as project manager.
He was also involved in the pilot program to introduce Quality by
Design into R&D. In 2013, he joined back ETH as senior researcher.
His current main research area is focused on the use of big data,
advanced statistics and machine learning in combination with
classical mechanistic models for risk management in R&D and
manufacturing of biomolecules. He is author of more than 60
papers on international peer reviewed journals and several book
chapters.
About the organisation:
ETH Zurich (Swiss Federal Institute of Technology
in Zurich) is a science, technology, engineering,
mathematics and management university in the city of Zürich,
Switzerland. The school was founded by the Swiss Federal
Governmentin1854withthestatedmissiontoeducateengineers
andscientists,serveasanationalcentreofexcellenceinscience
and technology and provide a hub for interaction between
the scientific community and industry. Twenty-one Nobel Prizes
have been awarded to students or professors of the Institute in
the past, allowing ETH Zurich to be consistently ranked among
the top universities in the world. It is currently ranked as 5th best
university in the world in engineering, science and technology.
The department of Chemistry and Applied Biosciences was one
of the original 6 departments at ETH’s foundation and today
counts 55 professors and more than 500 PhD students. The group
of Prof. Morbidelli, whom Dr. Butté is member of, counts 4 senior
researchers / lecturers, 7 post-docs and 21 PhD students in basic
research and applied basic research.
Workshop Leader:
Alessandro Butté, Lecturer, ETH Zurich
HALF-DAY PRE-CONFERENCE WORKSHOP
Wednesday 5th July 2017
13.30 – 17.30
Holiday Inn Kensington Forum, London, UK

6. PEPTIDES
Conference: Thursday 6th & Friday 7th July 2017, Holiday Inn Kensington Forum, London, UK Workshop: Wednesday 5th July 2017, London, UK
4 WAYS TO REGISTER
www.peptidesevent.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced specifically to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-215 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-215
EARLY BIRD
DISCOUNT
□ Book by 31st March 2017 to receive £400 off the conference price
□ Book by 28th April 2017 to receive £200 off the conference price
□ Book by 31st May 2017 to receive £100 off the conference price
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
DOCUMENTATION
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop A □ B □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops £1198.00 + VAT £1437.60
□ 1 Workshop only A □ B □ £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
Fateja Begum